GlaxoSmithKline’s anti-Nogo A drug (GSK1223249) was reported to be safe in ALS patients in a first in human clinical trial. The small phase I study also hinted at the drug’s efficacy by showing trends in respiratory function and muscle strength improvements. Nogo-A, a protein found to impair neuron regeneration, is found at higher than normal levels in people with ALS. A larger clinical trial is expected in 2012.
Click here to read more.Share this: